A vs AJG Stock Comparison

Scores Breakdown

Metric	A	AJG
📈 Growth	26/30	22/30
💰 Profitability	17/20	19/20
🏦 Financial Health	15/20	15/20
💵 Valuation	16/20	12/20
⚠️ Risk (lower is better)	5/10	4/10
Overall Score	79/100	74/100

Metric

AJG

📈 Growth

26/30

22/30

💰 Profitability

17/20

19/20

🏦 Financial Health

15/20

💵 Valuation

16/20

12/20

⚠️ Risk (lower is better)

5/10

4/10

Overall Score

79/100

74/100

Side-by-Side Summaries

A Analysis	AJG Analysis
📈 Growth & Financial Trajectory Eight quarters show revenue rising from about $1.66B in 2024-Q1 to about $1.84B in 2026-Q2, while Net Income fluctuates but trends higher, with a peak near $434M in 2025-Q4 and a pace around $300–$339M in other quarters. The trend depicts steady top-line growth and durable earnings power despite quarterly volatility. 💰 Margins & Cash Flow Gross Margin remains in the low-to-mid 50s% (roughly 53%), and Operating Margin sits in the low- to mid-20s% (roughly 21%). Cash flow remains broadly positive; Net Cash Flow From Operating Activities ranges in the hundreds of millions per quarter, while investing and financing activities swing, producing occasional negative free cash flow but overall liquidity. 🛡️ Balance Sheet & Liquidity Assets run around $12.8–$13.0B, with long-term debt near $3.0B and equity attributable to parent around $6.1–7.0B. Current assets ($4.2–4.9B) cover current liabilities ($1.9–2.3B), indicating solid liquidity and resilience, despite occasional negative equity readings due to accounting structure. ⚠️ Key Drivers & Risks Drivers: Life sciences instrumentation demand; continued R&D activity driving consumables and systems adoption. Risks: Cyclicality of lab spending; valuation sensitivity and dependence on continued margin stability.	📈 Growth & Financial Trajectory From Q3 2024 to Q2 2026 AJG grew revenue from $2.8068B to $4.003B (+~42%), while net income to parent rose from $314.1M to $324.0M (+~3%). The trend shows a strong top‑line expansion with earnings generally steady in later quarters. 💰 Margins & Cash Flow Operating margins remained high, averaging about 82%, with a dip in Q1 2025; margins remain robust. Cash flow was positive from operating activities in most quarters (e.g., $10M in Q2 2026) with investing outflows offset by financing activity, supporting solid cash generation. 🛡️ Balance Sheet & Liquidity Total assets near $81.8B and liabilities around $58.1B in Q2 2026, with equity ~$23.7B. Current ratio near 1.05x, noncurrent liabilities around $14.9B. Leverage is moderate and liquidity resilient. ⚠️ Key Drivers & Risks Drivers: Stable insurance brokerage demand and diversified client base; potential uplift from operational leverage. Risks: Earnings volatility across quarters; sensitivity to macro/regulatory cycles and valuation sensitivity due to leverage.

A Analysis

AJG Analysis

📈 Growth & Financial Trajectory

Eight quarters show revenue rising from about $1.66B in 2024-Q1 to about $1.84B in 2026-Q2, while Net Income fluctuates but trends higher, with a peak near $434M in 2025-Q4 and a pace around $300–$339M in other quarters. The trend depicts steady top-line growth and durable earnings power despite quarterly volatility.

💰 Margins & Cash Flow

Gross Margin remains in the low-to-mid 50s% (roughly 53%), and Operating Margin sits in the low- to mid-20s% (roughly 21%). Cash flow remains broadly positive; Net Cash Flow From Operating Activities ranges in the hundreds of millions per quarter, while investing and financing activities swing, producing occasional negative free cash flow but overall liquidity.

🛡️ Balance Sheet & Liquidity

Assets run around $12.8–$13.0B, with long-term debt near $3.0B and equity attributable to parent around $6.1–7.0B. Current assets ($4.2–4.9B) cover current liabilities ($1.9–2.3B), indicating solid liquidity and resilience, despite occasional negative equity readings due to accounting structure.

⚠️ Key Drivers & Risks

Drivers: Life sciences instrumentation demand; continued R&D activity driving consumables and systems adoption.
Risks: Cyclicality of lab spending; valuation sensitivity and dependence on continued margin stability.

📈 Growth & Financial Trajectory

From Q3 2024 to Q2 2026 AJG grew revenue from $2.8068B to $4.003B (+~42%), while net income to parent rose from $314.1M to $324.0M (+~3%). The trend shows a strong top‑line expansion with earnings generally steady in later quarters.

💰 Margins & Cash Flow

Operating margins remained high, averaging about 82%, with a dip in Q1 2025; margins remain robust. Cash flow was positive from operating activities in most quarters (e.g., $10M in Q2 2026) with investing outflows offset by financing activity, supporting solid cash generation.

🛡️ Balance Sheet & Liquidity

Total assets near $81.8B and liabilities around $58.1B in Q2 2026, with equity ~$23.7B. Current ratio near 1.05x, noncurrent liabilities around $14.9B. Leverage is moderate and liquidity resilient.

⚠️ Key Drivers & Risks

Drivers: Stable insurance brokerage demand and diversified client base; potential uplift from operational leverage.
Risks: Earnings volatility across quarters; sensitivity to macro/regulatory cycles and valuation sensitivity due to leverage.

A vs AJG Stock Comparison

Scores Breakdown

Side-by-Side Summaries

📈 Growth & Financial Trajectory

💰 Margins & Cash Flow

🛡️ Balance Sheet & Liquidity

⚠️ Key Drivers & Risks

📈 Growth & Financial Trajectory

💰 Margins & Cash Flow

🛡️ Balance Sheet & Liquidity

⚠️ Key Drivers & Risks

Similar Companies

Top Rated Companies